Diabetic Kidney Disease: A Report From an ADA Consensus Conference
Tóm tắt
Từ khóa
Tài liệu tham khảo
de Boer, 2011, Temporal trends in the prevalence of diabetic kidney disease in the United States, JAMA, 305, 2532, 10.1001/jama.2011.861
Collins, 2014, US Renal Data System 2013 annual data report, Am J Kidney Dis, 63, e219
Collins, 2014, US Renal Data System 2013 annual data report, Am J Kidney Dis, 63, e112
2007, KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease, Am J Kidney Dis, 49, S12
Magee, 2009, Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis, Diabetologia, 52, 691, 10.1007/s00125-009-1268-0
Zatz, 1986, Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension, J Clin Invest, 77, 1925, 10.1172/JCI112521
Evans, 2012, Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial, Nephrol Dial Transplant, 27, 2255, 10.1093/ndt/gfr696
Holtkamp, 2011, An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function, Kidney Int, 80, 282, 10.1038/ki.2011.79
Bakris, 2014, Microalbuminuria as a risk predictor in diabetes: the continuing saga, Diabetes Care, 37, 867, 10.2337/dc13-1870
Bilous, 2008, Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?, Diabet Med, 25, 25, 10.1111/j.1464-5491.2008.02496.x
Nosadini, 2000, Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate, Diabetes, 49, 476, 10.2337/diabetes.49.3.476
MacIsaac, 2004, Nonalbuminuric renal insufficiency in type 2 diabetes, Diabetes Care, 27, 195, 10.2337/diacare.27.1.195
He, 2013, Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis, Diabetologia, 56, 457, 10.1007/s00125-012-2796-6
Bachmann, 2014, State of the art for measurement of urine albumin: comparison of routine measurement procedures to isotope dilution tandem mass spectrometry, Clin Chem, 60, 471, 10.1373/clinchem.2013.210302
2000, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy, Lancet, 355, 253, 10.1016/S0140-6736(99)12323-7
Patel, 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med, 358, 2560, 10.1056/NEJMoa0802987
Bilous, 2010
Saydah, 2013, Albuminuria prevalence in first morning void compared with previous random urine from adults in the National Health and Nutrition Examination Survey, 2009-2010, Clin Chem, 59, 675, 10.1373/clinchem.2012.195644
Perkins, 2003, Regression of microalbuminuria in type 1 diabetes, N Engl J Med, 348, 2285, 10.1056/NEJMoa021835
2014, Standards of medical care in diabetes—2014, Diabetes Care, 37, S14
National Kidney Disease Education Program. Available from: http://nkdep.nih.gov/. Accessed 19 May 2014.
2013, KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, Kidney Int, 3, S1
Ismail-Beigi, 2010, Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial, Lancet, 376, 419, 10.1016/S0140-6736(10)60576-4
Rossing, 2006, Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005, Diabetologia, 49, 11, 10.1007/s00125-005-0077-3
Qaseem, 2013, Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians, Ann Intern Med, 159, 835, 10.7326/0003-4819-159-11-201312030-00009
Fox, 2012, Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis, Lancet, 380, 1662, 10.1016/S0140-6736(12)61350-6
Tonelli, 2012, Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study, Lancet, 380, 807, 10.1016/S0140-6736(12)60572-8
Groop, 2009, The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes, Diabetes, 58, 1651, 10.2337/db08-1543
Afkarian, 2013, Kidney disease and increased mortality risk in type 2 diabetes, J Am Soc Nephrol, 24, 302, 10.1681/ASN.2012070718
Borch-Johnsen, 1985, The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus, Diabetologia, 28, 590, 10.1007/BF00281993
Tonelli, 2013, Association between LDL-C and risk of myocardial infarction in CKD, J Am Soc Nephrol, 24, 979, 10.1681/ASN.2012080870
Palmer, 2012, Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis, Ann Intern Med, 157, 263, 10.7326/0003-4819-157-4-201208210-00007
Haynes, 2014, Effects of lowering LDL cholesterol on progression of kidney disease, J Am Soc Nephrol, 25, 1825, 10.1681/ASN.2013090965
Wanner, 2014, KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient, Kidney Int, 85, 1303, 10.1038/ki.2014.31
Holdaas, 2005, Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study, Am J Transplant, 5, 2929, 10.1111/j.1600-6143.2005.01105.x
Jun, 2012, Effects of fibrates in kidney disease: a systematic review and meta-analysis, J Am Coll Cardiol, 60, 2061, 10.1016/j.jacc.2012.07.049
Ansquer, 2008, Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people, Am J Kidney Dis, 51, 904, 10.1053/j.ajkd.2008.01.014
Wheeler, 2013, Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?, Kidney Int, 83, 377, 10.1038/ki.2012.425
James, 2014, 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8), JAMA, 311, 507, 10.1001/jama.2013.284427
Taler, 2013, KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD, Am J Kidney Dis, 62, 201, 10.1053/j.ajkd.2013.03.018
Pogue, 2009, Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease, Hypertension, 53, 20, 10.1161/HYPERTENSIONAHA.108.115154
Messerli, 2006, Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?, Ann Intern Med, 144, 884, 10.7326/0003-4819-144-12-200606200-00005
Peralta, 2012, Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP), Arch Intern Med, 172, 41, 10.1001/archinternmed.2011.619
Kovesdy, 2013, Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study, Ann Intern Med, 159, 233, 10.7326/0003-4819-159-4-201308200-00004
Wake Forest Baptist Health. Systolic Blood Pressure Intervention Trial. Available from: http://clinicaltrials.gov/ct2/show/NCT01206062?term=nct01206062&rank=1. Accessed 19 May 2014.
Lewis, 1993, The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy, N Engl J Med, 329, 1456, 10.1056/NEJM199311113292004
Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161
Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303
Fried, 2013, Combined angiotensin inhibition for the treatment of diabetic nephropathy, N Engl J Med, 369, 1892, 10.1056/NEJMoa1303154
Parving, 2012, Cardiorenal end points in a trial of aliskiren for type 2 diabetes, N Engl J Med, 367, 2204, 10.1056/NEJMoa1208799
Mann, 2008, Renal Outcomes With Telmisartan, Ramipril, or Both, in People at High Vascular Risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial, Lancet, 372, 547, 10.1016/S0140-6736(08)61236-2
European Medicines Agency. Renin-angiotensin-system (RAS)-acting agents. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Renin-angiotensin_system_(RAS)-acting_agents/human_referral_prac_000026.jsp&mid=WC0b01ac05805c516f. Accessed 19 May 2014.
Mehdi, 2009, Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy, J Am Soc Nephrol, 20, 2641, 10.1681/ASN.2009070737
Pitt, 2008, Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), Circulation, 118, 1643, 10.1161/CIRCULATIONAHA.108.778811
Toto, 2012, RAS blockade, hyperkalemia and AKI—look and you will find, Nat Rev Nephrol, 8, 257, 10.1038/nrneph.2012.62
Kohan, 2011, Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy, J Am Soc Nephrol, 22, 763, 10.1681/ASN.2010080869
AbbVie. A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study of Diabetic Nephropathy With Atrasentan. Available from: http://clinicaltrials.gov/show/NCT01858532. Accessed 19 May 2014.
Briasoulis, 2014, The future of interventional management of hypertension: threats and opportunities, Curr Vasc Pharmacol, 12, 69, 10.2174/15701611113119990137
Bhatt, 2014, A controlled trial of renal denervation for resistant hypertension, N Engl J Med, 370, 1393, 10.1056/NEJMoa1402670
Bisognano, 2011, Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial, J Am Coll Cardiol, 58, 765, 10.1016/j.jacc.2011.06.008
Nathan, 2008, Translating the A1C assay into estimated average glucose values, Diabetes Care, 31, 1473, 10.2337/dc08-0545
Ansari, 2003, Assessing glycemic control in patients with diabetes and end-stage renal failure, Am J Kidney Dis, 41, 523, 10.1053/ajkd.2003.50114
Vos, 2011, Red blood cell survival in long-term dialysis patients, Am J Kidney Dis, 58, 591, 10.1053/j.ajkd.2011.03.031
Nakao, 1998, Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis, Intern Med, 37, 826, 10.2169/internalmedicine.37.826
Miller, 2010, The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study, BMJ, 340, b5444, 10.1136/bmj.b5444
Shurraw, 2011, Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study, Arch Intern Med, 171, 1920, 10.1001/archinternmed.2011.537
Kalantar-Zadeh, 2012, A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: A1C remains the gold standard outcome predictor in diabetic dialysis patients, Diabetes Care, 35, 1625, 10.2337/dc12-0483
Ramirez, 2012, Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS), Diabetes Care, 35, 2527, 10.2337/dc12-0573
Kim, 2012, Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction, Diabetes Care, 35, 281, 10.2337/dc11-1462
Inaba, 2007, Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection, J Am Soc Nephrol, 18, 896, 10.1681/ASN.2006070772
Freedman, 2011, Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients, Clin J Am Soc Nephrol, 6, 1635, 10.2215/CJN.11491210
Gerich, 2001, Renal gluconeogenesis: its importance in human glucose homeostasis, Diabetes Care, 24, 382, 10.2337/diacare.24.2.382
2012, KDOQI clinical practice guideline for diabetes and CKD: 2012 update, Am J Kidney Dis, 60, 850, 10.1053/j.ajkd.2012.07.005
Mühlhauser, 1991, Severe hypoglycemia in type I diabetic patients with impaired kidney function, Diabetes Care, 14, 344, 10.2337/diacare.14.4.344
Scheen, 2013, Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease, Expert Opin Drug Metab Toxicol, 9, 529, 10.1517/17425255.2013.777428
Charpentier, 2000, Management of drugs affecting blood glucose in diabetic patients with renal failure, Diabetes Metab, 26, 73
Burrows, 2010, Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline, Diabetes Care, 33, 73, 10.2337/dc09-0343
Adler, 2003, Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64), Kidney Int, 63, 225, 10.1046/j.1523-1755.2003.00712.x
Zammitt, 2005, Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities, Diabetes Care, 28, 2948, 10.2337/diacare.28.12.2948
Whitmer, 2009, Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus, JAMA, 301, 1565, 10.1001/jama.2009.460
Ismail-Beigi, 2011, Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials, Ann Intern Med, 154, 554, 10.7326/0003-4819-154-8-201104190-00007
Roberts, 2007, The safety of metformin in heart failure, Ann Pharmacother, 41, 642, 10.1345/aph.1H523
Lipska, 2011, Use of metformin in the setting of mild-to-moderate renal insufficiency, Diabetes Care, 34, 1431, 10.2337/dc10-2361
Kalantar-Zadeh, 2013, Case records of the Massachusetts General Hospital. Case 23-2013. A 54-year-old woman with abdominal pain, vomiting, and confusion, N Engl J Med, 369, 374, 10.1056/NEJMcpc1208154
Salpeter, 2010, Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus, Cochrane Database Syst Rev, 4, CD002967
Rachmani, 2002, Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications, Eur J Intern Med, 13, 428, 10.1016/S0953-6205(02)00131-0
Rydberg, 1994, Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans, Diabetes Care, 17, 1026, 10.2337/diacare.17.9.1026
Holstein, 2001, Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide, Diabetes Metab Res Rev, 17, 467, 10.1002/dmrr.235
Harrower, 1996, Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency, Clin Pharmacokinet, 31, 111, 10.2165/00003088-199631020-00003
Balant, 1973, Pharmacokinetics of glipizide in man: influence of renal insufficiency, Diabetologia, 9, 331, 10.1007/BF01218443
Nagai, 2003, Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure, Diabetes Res Clin Pract, 59, 191, 10.1016/S0168-8227(02)00242-5
Hasslacher, 2003, Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function, Diabetes Care, 26, 886, 10.2337/diacare.26.3.886
Budde, 2003, The pharmacokinetics of pioglitazone in patients with impaired renal function, Br J Clin Pharmacol, 55, 368, 10.1046/j.1365-2125.2003.01785.x
Chapelsky, 2003, Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency, J Clin Pharmacol, 43, 252, 10.1177/0091270002250602
Thompson-Culkin, 2002, Pharmacokinetics of rosiglitazone in patients with end-stage renal disease, J Int Med Res, 30, 391
Grey, 2008, Skeletal toxicity of thiazolidinediones, Ann Intern Med, 148, 563, 10.7326/0003-4819-148-7-200804010-00020
US Food and Drug Administration. Drug safety information for healthcare professionals—information for healthcare professionals: reports of altered kidney function in patients using exenatide (marketed as Byetta). Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm188656.htm. Accessed 19 May 2014.
Tuttle, 2013, Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes, Am J Kidney Dis, 62, 396, 10.1053/j.ajkd.2013.03.026
Pawaskar, 2014, Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine, Ann Pharmacother, 48, 571, 10.1177/1060028013520597
Davidson, 2011, Mild renal impairment and the efficacy and safety of liraglutide, Endocr Pract, 17, 345, 10.4158/EP10215.OR
Pendergrass, 2012, Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis, Diabetes Obes Metab, 14, 596, 10.1111/j.1463-1326.2012.01567.x
Deacon, 2012, Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis, Diabetes Obes Metab, 14, 762, 10.1111/j.1463-1326.2012.01603.x
Aroda, 2012, Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review, Clin Ther, 34, 1247, 10.1016/j.clinthera.2012.04.013
2014
2013
2013
2014
Friedrich, 2013, Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes, Am J Ther, 20, 618, 10.1097/MJT.0b013e31826232dc
Kim, 2013, Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis, Diabetologia, 56, 696, 10.1007/s00125-012-2827-3
Neumiller, 2010, Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus, Drugs, 70, 377, 10.2165/11318680-000000000-00000
Kohan, 2014, Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control, Kidney Int, 85, 962, 10.1038/ki.2013.356
Yale, 2013, Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease, Diabetes Obes Metab, 15, 463, 10.1111/dom.12090
Cherney, 2014, Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus, Circulation, 129, 587, 10.1161/CIRCULATIONAHA.113.005081
Meloni, 2002, Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks?, J Ren Nutr, 12, 96
Wrone, 2003, Association of dietary protein intake and microalbuminuria in healthy adults: Third National Health and Nutrition Examination Survey, Am J Kidney Dis, 41, 580, 10.1053/ajkd.2003.50119
Hoogeveen, 1998, Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study, Kidney Int, 54, 203, 10.1038/sj.ki.4495353
Knight, 2003, The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency, Ann Intern Med, 138, 460, 10.7326/0003-4819-138-6-200303180-00009
Bernstein, 2010, Major dietary protein sources and risk of coronary heart disease in women, Circulation, 122, 876, 10.1161/CIRCULATIONAHA.109.915165
Cirillo M, Lombardi C, Chiricone D, De Santo NG, Zanchetti A, Bilancio G. Protein intake and kidney function in the middle-age population: contrast between cross-sectional and longitudinal data [published online ahead of print March 21, 2014]. Nephrol Dial Transplant. http://dx.doi.org/10.1093/ndt/gfu056.
Estruch, 2013, Primary prevention of cardiovascular disease with a Mediterranean diet, N Engl J Med, 368, 1279, 10.1056/NEJMoa1200303
Sacks, 1995, Rationale and design of the Dietary Approaches to Stop Hypertension trial (DASH). A multicenter controlled-feeding study of dietary patterns to lower blood pressure, Ann Epidemiol, 5, 108, 10.1016/1047-2797(94)00055-X
Odermatt, 2011, The Western-style diet: a major risk factor for impaired kidney function and chronic kidney disease, Am J Physiol Renal Physiol, 301, F919, 10.1152/ajprenal.00068.2011
Goldstein-Fuchs DJ, LaPierra AF. Nutrition and Kidney Disease. National Kidney Foundation. National Kidney Foundation’s primer on kidney diseases. 6th ed. Gilbert SJ, Weiner DE, Gipson DS, Perazella MA, Tonelli M, Eds. Philadelphia, PA, Elsevier/Saunders, 2014, p. 467-475.
Pijls, 2002, Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: a randomized trial, Eur J Clin Nutr, 56, 1200, 10.1038/sj.ejcn.1601474
Dussol, 2005, A randomized trial of low-protein diet in type 1 and in type 2 diabetes mellitus patients with incipient and overt nephropathy, J Ren Nutr, 15, 398
Pedrini, 1996, The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis, Ann Intern Med, 124, 627, 10.7326/0003-4819-124-7-199604010-00002
Robertson, 2007, Protein restriction for diabetic renal disease, Cochrane Database Syst Rev, 4, CD002181
Hansen, 1999, Low-protein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy, Kidney Int, 55, 621, 10.1046/j.1523-1755.1999.00274.x
Kasiske, 1998, A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function, Am J Kidney Dis, 31, 954, 10.1053/ajkd.1998.v31.pm9631839
Raal, 1994, Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-mo prospective study, Am J Clin Nutr, 60, 579, 10.1093/ajcn/60.4.579
Dullaart, 1993, Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension, Diabetes Care, 16, 483, 10.2337/diacare.16.2.483
Hansen, 2002, Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy, Kidney Int, 62, 220, 10.1046/j.1523-1755.2002.00421.x
Pan, 2008, Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials, Am J Clin Nutr, 88, 660, 10.1093/ajcn/88.3.660
Evert, 2014, Nutrition therapy recommendations for the management of adults with diabetes, Diabetes Care, 37, S120, 10.2337/dc14-S120
Shapiro, 2011, Effects of polyunsaturated fatty acid consumption in diabetic nephropathy, Nat Rev Nephrol, 7, 110, 10.1038/nrneph.2010.156
Lee, 2010, Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: cohort analysis of the diabetes control and complications trial, Diabetes Care, 33, 1454, 10.2337/dc09-2245
Kovesdy, 2008, Glycemic control in diabetic CKD patients: where do we stand?, Am J Kidney Dis, 52, 766, 10.1053/j.ajkd.2008.04.011
Kalantar-Zadeh, 2006, Epidemiology of dialysis patients and heart failure patients, Semin Nephrol, 26, 118, 10.1016/j.semnephrol.2005.09.005
Kalantar-Zadeh, 2003, Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients, Kidney Int, 63, 793, 10.1046/j.1523-1755.2003.00803.x
Kalantar-Zadeh, 2007, What is so bad about reverse epidemiology anyway?, Semin Dial, 20, 593, 10.1111/j.1525-139X.2007.00360.x
Kalantar-Zadeh, 2005, Causes and consequences of the reverse epidemiology of body mass index in dialysis patients, J Ren Nutr, 15, 142
Kalantar-Zadeh, 2005, Obesity paradox as a component of reverse epidemiology in heart failure, Arch Intern Med, 165, 1797, 10.1001/archinte.165.15.1797-a
Kalantar-Zadeh, 2005, Reverse epidemiology: a spurious hypothesis or a hardcore reality?, Blood Purif, 23, 57, 10.1159/000082012
Kalantar-Zadeh, 2005, Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions, Hypertension, 45, 811, 10.1161/01.HYP.0000154895.18269.67
Schumock, 2009, Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients, Nephron Clin Pract, 113, c54, 10.1159/000228076
Rhee, 2014, Updates on the management of diabetes in dialysis patients, Semin Dial, 27, 135, 10.1111/sdi.12198
Park, 2012, Glycemic control in diabetic dialysis patients and the burnt-out diabetes phenomenon, Curr Diab Rep, 12, 432, 10.1007/s11892-012-0286-3
Kalantar-Zadeh, 2009, Burnt-out diabetes: impact of chronic kidney disease progression on the natural course of diabetes mellitus, J Ren Nutr, 19, 33
Ricks, 2012, Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study, Diabetes, 61, 708, 10.2337/db11-1015
Kalantar-Zadeh, 2007, A1C and survival in maintenance hemodialysis patients, Diabetes Care, 30, 1049, 10.2337/dc06-2127
Hoshino, 2013, Using hemoglobin A1c to derive mean blood glucose in peritoneal dialysis patients, Am J Nephrol, 37, 413, 10.1159/000349929
Duong, 2011, Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus, Clin J Am Soc Nephrol, 6, 1041, 10.2215/CJN.08921010
Molnar, 2011, Associations of pretransplant serum albumin with post-transplant outcomes in kidney transplant recipients, Am J Transplant, 11, 1006, 10.1111/j.1600-6143.2011.03480.x
Sarno, 2013, New-onset diabetes mellitus: predictive factors and impact on the outcome of patients undergoing liver transplantation, Curr Diabetes Rev, 9, 78, 10.2174/157339913804143234
Chakkera, 2013, Calcineurin inhibition and new-onset diabetes mellitus after transplantation, Transplantation, 95, 647, 10.1097/TP.0b013e31826e592e
Chakkera, 2013, Can new-onset diabetes after kidney transplant be prevented?, Diabetes Care, 36, 1406, 10.2337/dc12-2067
2013, Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial, Diabetes Care, 36, 1735, 10.2337/dc12-2420
Marcovecchio, 2014, Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT): urinary screening and baseline biochemical and cardiovascular assessments, Diabetes Care, 37, 805, 10.2337/dc13-1634
Demirel, 2013, Microvascular complications in adolescents with type 1 diabetes mellitus, J Clin Res Pediatr Endocrinol, 5, 145, 10.4274/Jcrpe.994
Pettitt, 2014, Prevalence of diabetes in U.S. youth in 2009: the SEARCH for Diabetes in Youth Study, Diabetes Care, 37, 402, 10.2337/dc13-1838
Dabelea, 2014, Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009, JAMA, 311, 1778, 10.1001/jama.2014.3201
Gaede, 2008, Effect of a multifactorial intervention on mortality in type 2 diabetes, N Engl J Med, 358, 580, 10.1056/NEJMoa0706245
Gaede, 2003, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes, N Engl J Med, 348, 383, 10.1056/NEJMoa021778
Shankar, 2006, The association among smoking, heavy drinking, and chronic kidney disease, Am J Epidemiol, 164, 263, 10.1093/aje/kwj173
Fox, 2004, Predictors of new-onset kidney disease in a community-based population, JAMA, 291, 844, 10.1001/jama.291.7.844
Robinson-Cohen, 2009, Physical activity and rapid decline in kidney function among older adults, Arch Intern Med, 169, 2116, 10.1001/archinternmed.2009.438
Chen, 2010, Effects of an exercise program on blood biochemical values and exercise stage of chronic kidney disease patients, J Nurs Res, 18, 98
Wang, 2008, Association between obesity and kidney disease: a systematic review and meta-analysis, Kidney Int, 73, 19, 10.1038/sj.ki.5002586
Morales, 2003, Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies, Am J Kidney Dis, 41, 319, 10.1053/ajkd.2003.50039
Chan, 2009, Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study, Diabetes Care, 32, 977, 10.2337/dc08-1908
Leung, 2005, Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy, Am J Med, 118, 1414, 10.1016/j.amjmed.2005.07.050
Olivarius, 2001, Randomised controlled trial of structured personal care of type 2 diabetes mellitus, BMJ, 323, 970, 10.1136/bmj.323.7319.970
Rossi, 2008, Baseline quality-of-care data from a quality-improvement program implemented by a network of diabetes outpatient clinics, Diabetes Care, 31, 2166, 10.2337/dc08-0469
Agency for Healthcare Research and Quality. Patient Self-Management Support Programs. An Evaluation [Internet], 2007. Available from http://www.ahrq.gov/research/findings/final-reports/ptmgmt/index.html. Accessed 19 May 2014.
World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Sabaté E, Ed. Geneva, World Health Organization, 2003, p. 198.
Ali, 2006, The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis, Diabet Med, 23, 1165, 10.1111/j.1464-5491.2006.01943.x
Palmer, 2013, Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies, Kidney Int, 84, 179, 10.1038/ki.2013.77
Renders, 2001, Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review, Diabetes Care, 24, 1821, 10.2337/diacare.24.10.1821
Shojania, 2006, Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis, JAMA, 296, 427, 10.1001/jama.296.4.427
2013, KDIGO clinical practice guideline for lipid management in chronic kidney disease, Kidney Int, 3, 259
2012, KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease, Kidney Int, 2, 337
Mitchell P, Wynia M, Golden R, et al. Core principles & values of effective team-based health care, 2012. Washington, DC, Institute of Medicine. Available from: http://www.iom.edu/Global/Perspectives/2012/TeamBasedCare.aspx. Accessed 19 May 2014.
Lee, 2009, The role of specialists in managing the health of populations with chronic illness: the example of chronic kidney disease, BMJ, 339, b2395, 10.1136/bmj.b2395
Lee, 2012, Effects of proactive population-based nephrologist oversight on progression of chronic kidney disease: a retrospective control analysis, BMC Health Serv Res, 12, 252, 10.1186/1472-6963-12-252
Bayliss, 2011, Multidisciplinary team care may slow the rate of decline in renal function, Clin J Am Soc Nephrol, 6, 704, 10.2215/CJN.06610810
Bojadzievski, 2011, Patient-centered medical home and diabetes, Diabetes Care, 34, 1047, 10.2337/dc10-1671